Human carboxylesterase (CES) 1 and CES2 are members of the serine hydrolase superfamily, and both exhibit broad substrate specificity and are involved in xenobiotic and endobiotic metabolism. Although expression of CES1 and CES2 occurs in several organs, their expression in liver and small intestine is predominantly attributed to CES1 and CES2, respectively. We successfully 
Introduction
Human carboxylesterases (CES) are members of the serine hydrolase superfamily. They are categorized as phase I drug-metabolizing enzymes that can hydrolyze a variety of ester-containing drugs and prodrugs, such as angiotensin-converting enzyme inhibitors (temocapril, cilazapril, quinapril, and imidapril) , anticancer drugs (irinotecan and capecitabine), and narcotics (cocaine, heroin, and meperidine) (Hosokawa, 2008) . In humans, most carboxylesterases that have been identified belong to the CES1 and CES2 family, and they are differentiated on the basis of tissue distribution, substrate specificity, immunological properties, and gene regulation. CES1 protein is expressed in many organs, especially in the liver, but its expression in the gastrointestinal tract is markedly low (Imai, 2006) . CES2 protein is also expressed in many extrahepatic tissues, especially in the gastrointestinal tract and at lower levels in the liver (Xu et al., 2002) . CES1 preferentially hydrolyzes substrates that, upon hydrolysis, yield a smaller alcohol group and larger acyl group, whereas CES2 prefers substrates that yield a larger alcohol group and smaller acyl group .
There are three CES1 forms present in the National Center for Biotechnology Information database, CES1 form a (CES1-a; accession number NM_001025195), form b (CES1-b; accession number AB119997), and form c (CES1-c; accession number BC012418). Sequence alignment indicated that CES1-b and CES1-c lack Ala18 near the N terminus (Fig. 1A) , whereas CES1-c lacks Gln362 in the proposed active site (Fleming et al., 2005) and several amino acids near the N terminus are different. Many recent studies have identified CES1-b in human livers by mRNA reverse transcription, purified enzyme analysis, and mRNA expression level (Danks et al., 1999; Tabata et al., 2004b; Hosokawa, 2008) . To understand the differences in the enzymatic activities between the CES1-b and CES1-c forms, and to identify the predominant CES1 form in human liver, we successfully expressed CES1-b, CES1-c, and CES2 in baculovirus-infected High Five insect cells. The data presented in this study suggest that fluorescein diacetate (FD) is a probe substrate for CES2, and CES1-b is the dominant form in human liver.
Materials and Methods
Enzyme Preparations. cDNAs of hCE1-b, hCE1-c, and hCE2 were cloned into an engineered baculovirus expression vector using EcoRI site and confirmed with DNA sequencing. The constructs were cotransfected into Sf9 insect cells using the BD BaculoGold Transfection Kit (BD Pharmingen, San Diego, CA). For each construct, 30 plaques were screened for activity. Two liters of High Five cells were infected and then incubated for 48 to 66 h at 27°C. Membrane fractions were collected to make recombinant enzyme microsomes. CES1-b, CES1-c, and CES2 were from BD Gentest (Woburn, MA). HLM was obtained from BD Gentest HLM 50 Donor Pool, HIM was obtained from BD Gentest pooled HIM, and control membrane protein was obtained from BD Gentest Insect Control.
Kinetic Curve Assays. Assays were conducted in 96-well plates at 37°C. The assay buffer was 0.1 M potassium phosphate, pH 7.4. Incubation time and protein concentration were chosen within a linear condition response. The final acetonitrile concentration was not greater than 1.5% for all assays. Assays were initiated by adding the substrate/buffer mix to the enzyme/buffer mix. For the 4-NPA assay, the protein concentration was 10 g/ml for HLM and 20 g/ml for HIM, CES1-b, CES1-c, and CES2. Formation of 4-nitrophenol from 4-NPA hydrolysis was monitored at 410 nm using A ϭ bc (b ϭ 11 mM
Ϫ1
). For the FD assay, protein concentration was 0.5 g/ml for HIM, 2.5 g/ml for HLM and CES2, and 50 g/ml for CES1-b and CES1-c. Product (fluorescein) was detected using excitation 483 nm, emission 525 nm, and b ϭ 554000 M Ϫ1 at a gain setting of 70 on a Safire 2 instrument (Tecan, Männedorf, Switzerland). The studies were conducted in triplicate. Kinetic parameters (K m and V max ) were determined by nonlinear regression analysis using the Michaelis-Menten equation.
Inhibition Assays. Assays were conducted in similar methods as stated above with 1 mM 4-NPA for the colorimetric assay and 5 M FD for the fluorescent assay. The maximal final concentration was 100 M for bis(4-nitrophenyl) phosphate (BNPP) and loperamide with a 3-fold serial dilution to obtain the lower inhibitor concentrations. Reactions were initiated by the addition of the substrate/buffer mix to the plate. Metabolite formation was less than 20% in all conditions. The studies were conducted in duplicate. The IC 50 value for each assay was determined by nonlinear regression using the 4-parameter Hill equation.
Specific Activity Assays. For the specific activity assays, the data from the top 4-NPA and FD assays were used. To determine the specific activity for methyl 4-nitrobenzoate (M4NB), enzyme solutions were diluted to 0.005 mg/ml (HLM, CES1-b, CES1-c) or 0.05 mg/ml (HIM, CES2) with 0.1 M potassium phosphate buffer, pH 7.4. The final substrate concentration was 500 M. After a 10-min incubation at 37°C, the reaction was terminated by the addition of an equal volume of ice-cold acetonitrile. After centrifugation, supernatant was injected onto a high-performance liquid chromatography column (Zorbax SB-C18, 250 ϫ 4.6 mm, 5 m; Agilent Technologies, Santa Clara, CA). Mobile phases were 0.1% trifluoroacetic acid in H 2 O (A) and 0.1% trifluoroacetic acid in acetonitrile (B). Separation was achieved with a gradient elution from 10% B to 90% B in 25 min. Column temperature was 45°C and the flow rate was 1 ml/min. The eluent was monitored at 274 nm. (Fleming et al., 2005) . Figure 1B was created with Chimera (Pettersen et al., 2004 (Table 1) . With M4NB as the substrate, CES1-b and CES2 had specific activities of 0.957 and 0.0990 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 , respectively. With FD as the substrate, CES1-b and CES2 had specific activities of 0.357 and 13.8 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 , respectively. Kinetics. The kinetics of CES1-b, CES1-c, and CES2 were compared with HLM and HIM using a common carboxylesterase substrate, 4-NPA (Li et al., 2005) (Fig. 2A) , and a fluorogenic esterase substrate, FD (Battin, 1997) (Fig. 2B) . All enzymes exhibited a typical Michaelis-Menten saturation curve. The kinetic parameters are summarized in Fig. 2C . With 4-NPA as the substrate, CES1-b, CES2, HIM, and HLM had similar K m values between 170 and 210 M, but CES1-c showed a 2-fold higher K m value (441 M). Both CES1-b and CES1-c had similar V max values near 1.7 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 , which was approximately half of the V max value for HLM (3.41 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 ). In addition, the V max values between CES2 and HIM were approximately 2-fold, 0.718 and 1.29 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 , respectively.
When FD was used as the substrate, all enzyme systems except CES1-b had similar K m values, near 4 M. CES1-c had a 2-fold higher K m value than CES1-b (1.94 M). The V max values for CES2, HIM, and HLM were 14.6, 39.5, and 18.5 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 , respectively, which are greater than 50-fold higher than CES1-b (0.307 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 ) and CES1-c (0.213 mol ⅐ mg Ϫ1 ⅐ min Ϫ1 ). Inhibition. The IC 50 values of the generic carboxylesterase inhibitor BNPP (Tabata et al., 2004a,b) and the CES2-specific inhibitor loperamide (Quinney et al., 2005) were compared with recombinant CESs and human tissues (Fig. 3) . When 4-NPA was used as the substrate, BNPP exhibited potent inhibition toward HLM, CES1-b, CES1-c, HIM, and CES2 with IC 50 values less than 1 M. With the same substrate 4-NPA, loperamide inhibited HIM and CES2 with similar IC 50 values near 1 M; however, it showed minimal inhibition against HLM, CES1-b, and CES1-c. When FD was used as the substrate, loperamide inhibited HLM (0.664 M) with similar IC 50 values as HIM (1.07 M) and CES2 (0.287 M) (Fig. 3) .
Discussion
Recombinant Enzymes Have Similar Characteristics as Native Enzymes. Sequence alignment indicated that the difference between CES1-a and CES1-b was due to the insertion of Ala18 near the N terminus (Fig. 1A) , whereas the differences between CES1-b and CES1-c were the deletion of Gln362 as well as several amino acid changes near the N terminus. The crystal structure of CES1-c in complex with the breast cancer drug tamoxifen (Fleming et al., 2005) (Protein Data Bank code 1YA4) indicated that the N-terminal residues were flexible and far from the active site, whereas Gln362 is adjacent to two substrate binding residues (Leu363 and Met364) in the active site (Fig. 1B) . Because Leu363 and Met364 are both involved in substrate binding, it is possible that CES1-a and CES1-b have similar substrate binding characteristics due to the presence of Gln362; however, the absence of Gln362 may alter the substrate binding for CES1-c.
The observed difference of K m values between CES1-b and CES1-c with 4-NPA and FD seems to be consistent with the crystal structure (Fig. 1B) . Leu363 and Met364 are two of the eight residues involved in tamoxifen binding, and the absence of Gln362 may change the geometry of the binding site and directly affect the affinity of the substrate and impact the K m value. Furthermore, Gln362 is away from the catalytic triad Ser221-His468-Glu354, which is on the other side of the active site, and the absence of Gln362 may have less of an effect on the maximal rate of enzyme catalysis. Although the k cat values for CES1-b and CES1-c are unknown, there seems to be comparable expression levels of CES1-b and CES1-c based on Western Blot analysis (data not shown) and similar V max values.
Because CES1 was more abundant than CES2 in liver, when 4-NPA was used, HLM activity is mainly attributed to CES1. Because the IC 50 values with BNPP and K m values with CES1-b and HLM are similar, the data suggest that CES1-b, or CES1-a, is the primary CES1 form in the liver. This conclusion seems to be supported by the results of other laboratories finding CES1-b but not CES1-a in human liver (Danks et al., 1999; Tabata et al., 2004b; Hosokawa et al., 2008) . Based upon these results, it is reasonable to conclude that CES1-b is the primary form in human liver. 
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The specific activity, K m values, and IC 50 values with CES1-b and CES2 match the values obtained in HLM or HIM, respectively, indicating that the insect cell-expressed recombinant enzymes have similar characteristics with the native enzymes. In spite of its structure, 4-NPA does not display the same substrate preference for CES1 or CES2 as other substrates. M4NB and FD prefer CES1 and CES2, respectively, favoring a larger acyl group or a larger alcohol group, respectively (Imai, 2006; Imai et al., 2006) . The specific activity comparison was in agreement with the previously reported trend.
FD Is a Probe Substrate for CES2. A previous study showed that purified recombinant CES1 and CES2 had similar k cat values with 4-NPA as the substrate (E. T. Williams, personal communication). In this study, the V max ratio with 4-NPA for recombinant CES1 over CES2 is 2:1, which indicates that the expression levels of CES1 over CES2 is roughly 2-fold. When FD was used as the substrate, CES2 had a 50-fold greater V max value than CES1, suggesting a roughly 100-fold greater k cat value for CES2 than CES1. Therefore, FD was a probe substrate for CES2. This was further confirmed by the observation that loperamide inhibited HLM with similar IC 50 values as HIM and CES2, when FD was used as the substrate. Although Western blot analysis (data not shown) and previous studies (Imai et al., 2006) indicated that HLM contains both CES1 and CES2, the high FD hydrolysis by HLM was most likely due to the presence of CES2 because the CES1 Supersomes showed substantially lower V max values. The structure of FD is also consistent with the proposed CE substrate selectivity .
The V max value of HIM was higher than HLM with FD as the substrate, which suggested that CES2 is less abundant in liver than in intestine, consistent with Western blot analysis (data not shown) and hydrolysis in a nondenaturing protein gel . High concentrations of loperamide inhibited HIM hydrolysis of 4-NPA by nearly 100%, suggesting that CES2 is the primary carboxylesterase in intestine. Both findings were consistent with a previous report of esterase activity in a nondenaturing protein gel .
Conclusions
In conclusion, FD was demonstrated as a fluorogenic in vitro CES2-selective probe substrate. In addition, the results further support that CES1-b is the major expressed form in human liver, and the K m difference of the CES1 forms may be explained by its structure. The insect cell-expressed recombinant enzymes have similar characteristics with native enzymes.
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